# Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)

> **NCT02567721** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 11530 (actual)

## Conditions studied

- Influenza

## Interventions

- **OTHER:** Vaccine safety surveillance

## Key facts

- **NCT ID:** NCT02567721
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 11530 (ACTUAL)
- **Last updated:** 2016-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567721, "Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02567721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*